Case Report

Full Regression of Peyronie’s Disease Plaque Following Combined Antioxidant Treatment: A Three-Case Report

Gianni Paulis 1,* and Giovanni De Giorgio 2

1 Peyronie’s Care Center, Department of Uro-Andrology, Castelfidardo Clinical Analysis Center, 00185 Rome, Italy
2 Ultrasound Diagnostics Section, Department of Uro-Andrology, Castelfidardo Clinical Analysis Center, 00185 Rome, Italy
* Correspondence: paulisg@libero.it; Tel.: +39-06-44232584

Abstract: Peyronie’s disease (PD) is a fibrotic disorder of the tunica albuginea of the penis. Conservative medical therapy includes oral and/or injective active substances. Until now, only two PD patients who recovered after medical treatment are described in the literature. This article describes three new cases of PD patients who achieved complete resorption of plaque following antioxidant treatment.

Case Presentations:

Case 1. The patient was a 34-year-old man, a smoker, with lateral-left penile curvature (40 degrees), penile pain, and good penile rigidity. The patient was treated with combined therapy (oral antioxidants + Propolis creme). At follow-up, after about 29 months of treatment, we observed the disappearance of the acquired penile deformity. The ultrasound examination no longer showed any plaque.

Case 2. The patient was a 32-year-old man with chronic prostatitis, penile lichen sclerosus, lateral-left penile curvature (10 degrees), a palpable lump, and good penile rigidity. The patient was treated with combined therapy (oral antioxidants + Propolis creme + penile injections of pentoxifylline). After 33 months of treatment, at follow-up, we observed the disappearance of the penile deformity. Ultrasound examinations no longer showed any plaque.

Case 3. The patient was a 33-year-old man with penile pain, dorsal penile curvature (30 degrees), and good penile rigidity. The patient was treated with combined therapy (oral antioxidants + Propolis creme + penile injections of pentoxifylline). At follow-up, after 41 months of treatment, the penile pain was no longer present, and the ultrasound study no longer showed any plaque. Conclusions: Although our study presents a limited number of cases, it is a matter of fact that these patients obtained full regression in the affected area. We believe our experience may be very useful for urological clinical practice.

Keywords: Peyronie’s disease; antioxidants; oxidative stress

1. Introduction

Peyronie’s disease (PD) affects adult men and is characterized by chronic inflammation of the penis (tunica albuginea). Its hallmark is the growth of fibrous plaque, which in certain cases becomes calcified and causes penile deformation. Symptoms of PD include penile deformity (curvature, shortening, divots, hourglass, etc.), penile pain, erectile dysfunction, and anxiety–depression [1–3]. The prevalence of PD varies between 3.2 and 13% [4,5]. Although the etiopathogenesis of the disease has not been fully explained yet, it is known that PD affects males with a genetic predisposition, and the triggering factor appears to be trauma, which need not necessarily be severe, and it is more or less associated with the presence of risk factors (diabetes, high blood pressure, chronic prostatitis, autoimmune disorders, etc.) [6–9]. Following the traumatic event, an accumulation of blood and fibrin forms in situ, causing the onset of the disease, with a strong recruitment of inflammatory cells leading to the overproduction of fibrogenic factors and reactive oxygen species (oxidative stress) [10,11]. It has recently been proved that the latter, in particular, plays a decisive role in the formation of plaque and the evolution of the disease itself [11–13].
Whereas surgery is the treatment of choice for stable-phase disease, in situations involving severe erectile dysfunction and/or severe penile curvature, which prevent penetration, conservative treatment is indicated in the active phase of the disease (inflammatory stage) and includes the following: oral vitamin E, potaba, colchicine, tamoxifen, antioxidants, and phosphodiesterase-5 inhibitors; penile-injections of anti-inflammatory agents, anti-fibrotic substances, and antioxidants (verapamil, corticosteroids, pentoxifylline, collagenase, interferon, etc.); and physical therapy (iontophoresis, ESWT, vacuum devices, and penile traction devices) [14–16]. This report presents three cases of patients with PD who were followed at our “PD Care Center” and who achieved full plaque resolution following multimodal treatment with antioxidants. This case report follows another article in which we described two other cases of full recovery from the disease following antioxidant treatment.

2. Case Presentations

2.1. Case 1

A 34-year-old Caucasian man, a smoker (10 cigarettes per day), with congenital lateral-left penile curvature (10 degrees before the onset of PD), penile pain, and normal penile rigidity presented at our clinic in April 2019, complaining of pain in the penis during erections and curvature of the penis which had begun 6 months prior. The visual analogue pain score (VAS) was 2 (scored from 0 to 10). The score on the International Index of Erectile Function (IIEF) questionnaire was 26. When administering the IIEF questionnaire, we took into consideration questions 1, 2, 3, 4, 5, and 15, which refer to the aspect of erectile function (normal range from 26 to 30). A penile Doppler ultrasound was performed (alprostadil 10 mcg). The penile deformity consisted of a lateral-left penile curvature of 40 degrees.

The arterial flow of the cavernous arteries and the end-diastolic velocity were normal: peak-systolic velocity = 92 cm/s (left) and 90 cm/s (right); end-diastolic velocity = 0 cm/s (on both sides). Three-dimensional measurements of the volume of plaque were taken using an ellipsoid formula (volume = 0.524 × width × length × thickness) [17,18].

The plaque was located in the middle of the penis, its ultrasound aspect was iso-hyperechoic, and it measured 10.8 × 10.1 × 3.03 mm (174 mm³ = volume) (Figure 1, Table 1).

![Figure 1. Ultrasonography of the penis before therapy (longitudinal and axial views).](image-url)
Table 1. Summary of the 3 cases of patients with Peyronie’s disease who were treated with multimodal antioxidant therapy.

| # | Age/Years | Concomitant Diseases | Localization of the Penile Plaque | Plaque Measurements (Length × Width × Thickness) and Volume of the Plaque (A) Prior and (B) After Therapy | Typology of the Curvature (A) Prior and (B) After Therapy | Penile Pain VAS Scale (Score 1 to 10) (A) Prior and (B) After Therapy | IIEF Questionnaire Score (A) Prior and (B) After Therapy | Duration of Therapy Up to Plaque Regression | Description of the Administered Multimodal Therapy |
|---|-----------|----------------------|----------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------|------------------------------------------------|------------------------------------------------|-----------------------------------------------|--------------------------------------------------|
| 1 | 34 years  | Congenital lateral-left penile curvature (10-degrees) | Middle third | (A) 10.8 × 10.1 × 3.03 mm volume = 174 mm³ | (A) 40-degree left curvature | (A) score 2 | (A) score 26 | 2 years and 5 months | orally: Silymarin 400 mg + Ginkgo biloba 250 mg + Propolis 600 mg + Bilberry 160 mg + Vitamin E 800 IU/once a day, for 29 months. + topically: Propolis creme/twice a day/for 29 months. * The patient refused peri-plaque penile injections |
|   |           |                      | (B) No plaque detected | (B) 10-degree left penile curvature (previous condition = congenital lateral left penile curvature) | (B) score 0 (after 12 months) | (B) score 26 |                                                |                                                |                                                |
| 2 | 32 years  | Lichen sclerosus, chronic prostatitis | Proximal third | (A) 16.4 × 8.27 × 3.09 mm volume = 219 mm³ | (A) 10-degree left curvature | (A) score 3 | (A) score 26 | 2 years and 9 months | orally: Silymarin 400 mg + Ginkgo biloba 250 mg + Propolis 600 mg + Bilberry 160 mg + Vitamin E 800 IU/once a day, for 33 months. + topically: Propolis creme/twice a day/for 33 months. + peri-plaque penile injections: Pentoxifylline 100 mg (30 G needle) every 15 days for 6 months, and then monthly for 12 months, and then 1 injection every other month, for 12 months (total = 30 injections) |
|   |           |                      | (B) No plaque detected | (B) None | (B) score 0 (after six months) | (B) score 28 |                                                |                                                |                                                |
| 3 | 33 years  | None | Middle third | (A) 20.6 × 15.2 × 4.42 mm volume = 724 mm³ + some small calcifications, the largest of which measured 1.9 × 4.1 mm | (A) 30-degree dorsal penile curvature | (A) score 2 | (A) score 26 | 3 years and 5 months | orally: Silymarin 400 mg + Ginkgo biloba 250 mg + Propolis 600 mg + Bilberry 160 mg + Vitamin E 800 IU/once a day, for 41 months. + topically: Propolis creme/twice a day/for 41 months. + peri-plaque penile injections: Pentoxifylline 100 mg (30 G needle) every 15 days for 6 months, and then monthly for 12 months, and then 1 injection every other month, for 12 months (total = 30 injections) |
|   |           |                      | (B) No plaque detected | (B) None | (B) score 0 (after six months) | (B) score 27 |                                                |                                                |                                                |

* Abbreviations: IIEF score = Erectile function scoring; VAS = Pain scoring.
During the informed consent process, the patient was told that treatment would necessarily be long due to the chronic nature of the disease. The patient refused to the publication of photos of his penis, even if they were anonymous. The patient refused to be treated with penile infiltrations for fear of pain. Beginning in April 2019, after giving his informed consent, the patient was treated with combined therapy: oral antioxidants silymarin 400 mg + Ginkgo biloba 250 mg + propolis 600 mg + bilberry 160 mg + vitamin E 800 IU/once a day/+ propolis creme/twice a day/for 12 months.

At the end of the first treatment cycle, at follow-up, the patient filled out the IIEF questionnaire, and the score was 26. We then observed a left penile curvature with a decreased angle (to 25 degrees). The pain in the penis had gone. The penile ultrasound showed the following dimensions: 6.33 × 5.58 × 2.66 mm (49 mm³ = volume) (Figure 2).

![Figure 2. Ultrasonography of the penis after the 1st therapy cycle (longitudinal and axial views).](image1)

Compared to its initial measurement, the plaque had therefore undergone a 71.8% reduction in volume. Considering the excellent result after the first therapy cycle, we repeated the treatment for another 6 months.

After the second treatment cycle, the IIEF score at follow-up was unchanged at 26, and we observed that the lateral-left penile curvature had an angle reduced to 20 degrees. The ultrasound showed the following dimensions: 3.98 × 3.33 × 2.20 mm (15 mm³ = volume) (Figure 3).

![Figure 3. Ultrasonography of the penis after the 2nd therapy cycle (longitudinal and axial views).](image2)

The volume of the plaque was thus 91.3% smaller. Considering the excellent result after the second therapy cycle, we decided to continue the same multimodal treatment for only another 6 months. However, the patient continued the same treatment for 9 months.
After three treatment cycles, for an overall 2 years and 5 months (29 months) of multimodal treatment, the IIEF score of the patient at follow-up was the same (scoring 26). We observed that the lateral-left penile curvature had an angle reduced to 10 degrees, similar to the curve present before PD (congenital curve). The ultrasound examination no longer showed any plaque (Figure 4).

![Figure 4. Ultrasonography of the penis after the 3rd therapy cycle. (A) Longitudinal view; (B) axial view.](image)

The ultrasonography was performed by the same physician at the patient’s initial presentation, as well as at the later follow-ups, and always using the same device (Philips Affinity 70 G).

The multimodal therapy with antioxidants was suspended. No side effects were reported by the patient after treatment.

### 2.2. Case 2

A 32-year-old Caucasian man, a non-smoker, with chronic prostatitis, penile lichen sclerosus, lateral-left penile curvature (10 degrees), penile pain, and normal penile rigidity, presented at our clinic in March 2017. At the time of our observation, the visual analogue pain score (VAS) was 3 (scored from 0 to 10).

The IIEF score was 26. Physical examination revealed, on palpation of the proximal third of the penis, a nodule measuring about 20 mm in length. A penile Doppler ultrasound was performed (alprostadil 10 mcg). The penile deformity consisted of lateral-left penile curvature (10 degrees). The arterial flow of the cavernous arteries and the end-diastolic velocity were normal: peak-systolic velocity = 95 cm/sec (left) and 92 cm/sec (right); end-diastolic velocity = 0 cm/s (on both sides). The plaque was located at the base of the penis, its ultrasound aspect was iso-hyperechoic, and it measured $16.4 \times 8.27 \times 3.09$ mm (219 mm$^3$ = volume) (Table 1, Figure 5).

![Figure 5. Ultrasonography of the penis before therapy (longitudinal and axial views).](image)
During the informed consent process, the patient was told that treatment would necessarily be long due to the chronic nature of the disease. The patient refused to the publication of photos of his penis, even if they were anonymous.

Beginning in May 2017, after giving his informed consent, the patient was treated with combined therapy: oral antioxidants silymarin 400 mg + Ginkgo biloba 250 mg + propolis 600 mg + bilberry 160 mg + vitamin E 800 IU/once a day/+ propolis creme/twice a day/+ penile injection (peri-plaque) with pentoxifylline (100 mg, using a 30G needle) every 15 days for 6 months.

At the end of the first treatment cycle, at a follow-up, the patient filled out the IIEF questionnaire, and the score was observed to have increased to 28.

We then observed a left penile curvature with a decreased angle (to 6 degrees). The penile pain was gone. In the previous examination, we used the ultrasound machine Philips HD 15; however, subsequently, the ultrasound machine in our clinic was replaced by a new machine (Philips Affinity 70 G), which was used in the latter and in subsequent follow-ups. The same doctor performed all the ultrasound examinations. The penile ultrasound showed the following plaque dimensions: \(12.9 \times 6.66 \times 3.01\ mm\) (135 mm\(^3\) = volume) (see Figure 6).

Figure 6. Ultrasonography of the penis after the 1st therapy cycle (longitudinal and axial views).

Compared to its initial measurement, the plaque had therefore undergone a 38.3% reduction in volume.

Considering the good result after the first therapy cycle, we repeated the same treatment for another 12 months (second cycle), while reducing the pentoxifylline 100 mg injection frequency to one penile peri-plaque injection every month.

At the end of the second cycle of treatment, the patient underwent follow-up with a physical exam and a penile Doppler ultrasound. At follow-up, the penile pain was no longer present, and the IIEF score was 28. We then observed a lateral-left penile curvature with an unchanged angle (6 degrees).

The penile ultrasound showed the following plaque dimensions: \(9.27 \times 5.86 \times 2.58\ mm\) (73 mm\(^3\) = volume) (Figure 7).

Compared to its initial measurement, the plaque had therefore undergone a 66.6% reduction in volume.

In consideration of the good response achieved, even with the second cycle of multimodal therapy, the decision was made to continue the same oral and topical treatment for a third cycle, while reducing the pentoxifylline 100 mg injection frequency to one penile peri-plaque injection every other month.

After the completion of the third treatment cycle, and after 2 years and 9 months (33 months), the patient underwent follow-up with a physical exam and a penile Doppler ultrasound. At follow-up, the IIEF score was 28. The penile pain was no longer present. We then observed an absence of penile deformation. The ultrasound examination no longer showed any plaque (Figure 8).
The multimodal therapy with antioxidants was suspended. No side effects were reported by the patient after treatment. The same physician performed all the ultrasonography examinations.

2.3. Case 3

A 33-year-old Caucasian man, a non-smoker, with dorsal penile curvature (30 degrees), a palpable nodule, and normal penile rigidity, presented at our clinic in May 2017, complaining of penile pain during erection, with an onset of about 1 year before.

The visual analogue pain score (VAS) was 2. The International Index of Erectile Function score was 26. On penile palpation, there was no evidence of any penile nodules.

A penile Doppler ultrasound was performed (alprostadil 10 mcg). The penile deformity consisted of dorsal penile curvature (30 degrees). The arterial flow of the cavernous arteries and the end-diastolic velocity were normal: peak-systolic velocity = 96 cm/s (left) and 94 cm/s (right); end-diastolic velocity = 0 cm/s (on both sides). The plaque was located in the middle of the penis, its ultrasound aspect was iso-hypoechoic, and it measured $20.6 \times 15.2 \times 4.42 \text{ mm} (724 \text{ mm}^3 = \text{ volume})$; within the plaque, there were some small calcifications, the largest of which measured $1.9 \times 4.1 \text{ mm}$ (Figure 9).

During the informed consent process, the patient was told that treatment would necessarily be long due to the chronic nature of the disease. The patient refused to the publication of photos of his penis, even if they were anonymous.
2.3. Case 3

A 33-year-old Caucasian man, a non-smoker, with dorsal penile curvature (30 degrees). The arterial flow of the cavernous arteries and the end-diastolic velocity were normal: peak-systolic velocity = 96 cm/sec (left) and 94 cm/sec (right); end-diastolic velocity = 0 cm/sec (on both sides). The penile ultrasound showed the following plaque dimensions: 9.14 × 7.62 × 1.27 mm (127 mm³ = volume) and the disappearance of the internal calcifications (Figure 10).

Beginning in May 2017, after giving his informed consent, the patient was treated with combined therapy: oral antioxidants silymarin 400 mg + Ginkgo biloba 250 mg + propolis 600 mg + bilberry 160 mg + vitamin E 800 IU/once a day/+ propolis creme/twice a day/+ penile injection (peri-plaque) of pentoxifylline (100 mg, using a 30 G needle) every 15 days for 6 months.

After the first treatment cycle, at follow-up, the patient filled out the IIEF questionnaire, and the score was 26. We then observed a dorsal penile curvature with a decreased angle (to 25 degrees). The penile pain was gone.

In the previous examination, we used the ultrasound machine Philips HD 15; subsequently, the ultrasound machine in our clinic was replaced by a new machine (Philips Affinity 70 G), which was used in the latter and subsequent follow-ups. The same doctor performed all the ultrasound examinations. The penile ultrasound showed the following dimensions: 14.1 × 8.54 × 3.74 mm (236 mm³ = volume) and the disappearance of the internal calcifications (Figure 10).

Compared to its initial measurement, the plaque had therefore undergone a 67.4% reduction in volume.

Considering the good result after the first therapy cycle, we repeated the same treatment for another 12 months (second cycle), while reducing the pentoxifylline 100 mg injection frequency to one penile peri-plaque injection every month.

Figure 9. Ultrasonography of the penis before therapy (longitudinal and axial views). (A) Entire plaque; (B) the largest calcification.

Figure 10. Ultrasonography of the penis after the 1st therapy cycle (longitudinal and axial views).
At the end of the second cycle of treatment, the patient underwent follow-up with a physical exam and a penile Doppler ultrasound. At follow-up, the IIEF score was 27. We then observed a dorsal penile curvature with an angle reduced to 15 degrees. The penile ultrasound showed the following plaque dimensions: $9.14 \times 7.62 \times 1.27$ mm ($127$ mm$^3$ = volume) (Figure 11).

Compared to its initial measurement, the plaque had therefore undergone an 82.4% reduction in volume. In consideration of the good response achieved, even with the second cycle of multimodal therapy, the decision was made to continue the same oral and topical treatment for a third cycle, while reducing the pentoxifylline 100 mg injection frequency to one penile peri-plaque injection every other month.

After the third treatment cycle, the patient underwent a similar follow-up with a physical exam and a penile Doppler ultrasound. The IIEF score was 27. We then observed a dorsal penile curvature of 15 degrees (unchanged). The penile ultrasound showed the following plaque dimensions: $4.95 \times 3.91 \times 2.02$ mm ($21$ mm$^3$ = volume) (Figure 12).

Compared to its initial measurement, the plaque had therefore undergone a 97% reduction in volume.

Considering the good result after the third therapy cycle, we repeated the same treatment (oral antioxidants + creme) for another 6 months (fourth cycle) and suspended the pentoxifylline injections.

After the fourth treatment cycle, the patient underwent a similar follow-up, and after 3 years and 5 months of multimodal treatment, the patient underwent the same follow-up with a physical exam and a penile Doppler ultrasound. The IIEF score was 27. We then observed an absence of penile deformation. The ultrasound examination no longer showed any plaque (Figure 13).

The multimodal therapy with antioxidants was suspended. No side effects were reported by the patient after treatment. The same physician performed all ultrasonography examinations.
After the third treatment cycle, the patient underwent a similar follow-up with a physical exam and a penile Doppler ultrasound. The IIEF score was 27. We then observed a dorsal penile curvature of 15 degrees (unchanged). The penile ultrasound showed the following plaque dimensions: 4.95 × 3.91 × 2.02 mm (21 mm$^3$ = volume) (Figure 12).

Figure 12. Ultrasonography of the penis after the 3rd therapy cycle. (A) Longitudinal view; (B) axial view.

Compared to its initial measurement, the plaque had therefore undergone a 97% reduction in volume.

Considering the good result after the third therapy cycle, we repeated the same treatment (oral antioxidants + creme) for another 6 months (fourth cycle) and suspended the pentoxifylline injections.

After the fourth treatment cycle, the patient underwent a similar follow-up, and after 3 years and 5 months of multimodal treatment, the patient underwent the same follow-up with a physical exam and a penile Doppler ultrasound. The IIEF score was 27. We then observed an absence of penile deformation. The ultrasound examination no longer showed any plaque (Figure 13).

Figure 13. Ultrasonography of the penis after the 3rd therapy cycle. (A) Longitudinal view; (B) axial view.

3. Discussion

In the literature, a number of studies have already described a reduction in PD plaque and an improvement in penile deformity [19–22]. In a recent article, we described two cases of PD patients who achieved a complete disappearance of plaque following multimodal treatment with antioxidants [23]. Before the publication of our last article, plaque disappearance in PD had already been reported, but in an article describing an experimental study on rats and not on men [24]. It may be noticed that our treatment required a lengthy period of time; this was necessary because PD is a “chronic” inflammatory disease and, consequently, complete resorption of the diseased area (plaque) requires a length of time that depends on the size of the plaque.

Although our article describes a limited number of cases, we think it is of great importance for the practice of all urologists.

We believe the success of our treatment lies in the properties of the antioxidant substances we used; these substances can interrupt the inflammatory process, combating oxidative stress, which has been shown to play an essential role in the production of fibrogenic factors [10]. All the antioxidants used in our combined treatment also have anti-inflammatory and anti-fibrotic properties, which block the production of pro-inflammatory cytokines, thanks to their inhibiting activity toward factor NF-kB [25–29].

Propolis, bilberry, silymarin, and Ginkgo biloba have the following action properties: antioxidant and anti-fibrotic activity; the inhibition of proinflammatory cytokines IL-6,
IL-8, TGF-beta 1, IL-1, and TNF-α; the inhibition of MMP-2 and MMP-9 (with anti-elastic activity); the inhibition of the COX-2 enzyme; the inhibition of the activation of the NF-kappa-B factor; PDGF-activity inhibition, etc. [12,26–29].

Vitamin E has the following action properties: scavenger activity against ROS, hydroxyl radicals, and lipid peroxyl radicals; NFK-B factor inhibition; proinflammatory cytokine-expression inhibition; COX-2 inhibition; PDGF-activity inhibition; and the inhibition of fibroblast proliferation [12].

Pentoxifylline has the following action properties: the inhibition of ROS and lipid oxidation; the inhibition of myofibroblastic differentiation of fibroblasts; a reduction in collagen deposition; NFK-B factor inhibition; proinflammatory cytokine-expression inhibition; COX-2 inhibition; TGF-beta-1 inhibition; PAI 1-expression inhibition; fibroblast apoptosis stimulation; non-specific PDE inhibitory power; and the downregulation of iNOS protein expression [12,25].

It may have been noticed that our treatment cycles call for a gradual lengthening of the interval between pentoxifylline injections. This treatment plan is dictated by the fact that even a simple perilesional injection represents a trauma, however minimal, and trauma is unquestionably the factor that triggers the disease [7,8]. Therefore, any time that follow-up showed a partial regression of PD, we found it right to reduce the possibility of any new trauma, however minimal, by more widely spacing out the injections.

Our multimodal therapy allowed penile plaque to regress and penile curvature improvement. In our treatment, the anti-inflammatory activity was completely natural and without the use of classic anti-inflammatories (non-steroidal anti-inflammatory/NSAIDs and steroidal substances). In the majority of cases, classic anti-inflammatory substances fail to cure PD; this is possibly due to a delayed onset of treatment, failure to adequately diagnose the presence of plaque, or inadequate treatment compliance.

With respect to diagnostic imaging, although sonographic assessment of the penis has been reported in the literature to be unable to provide adequate plaque measurements, we believe, instead, that accurate plaque size can be obtained if a highly sensitive, state-of-the-art ultrasound machine is employed, and, above all, if the evaluation is performed by a physician experienced in the diagnosis of this disease [30–32]. We, therefore, believe we owe our results not only to the substances used in the course of the therapy, but also to the characteristics of our ultrasound assessment, which enabled us to accurately diagnose the area affected by the disease (plaque) and constantly monitor the evolution of the disease at scheduled follow-ups.

4. Conclusions

Although our study presents a very limited number of cases, it is a matter of fact that these patients obtained full regression in the affected area.

We believe our success was due essentially to three important factors: the type of antioxidant substances; the use of an extremely sensitive ultrasound machine, which was able to provide the precise dimensions of the plaque; and, moreover, the fact that the scan was performed by a physician with extensive experience in Peyronie’s disease. We believe our experience, however limited, may be very useful for the clinical practice of specialists in the field of uro-andrology. In any case, randomized controlled studies with a greater number of cases are desirable and needed to prove the effectiveness of this type of treatment for PD.

Author Contributions: G.P. and G.D.G. contributed to the complete realization of the article. Both authors have read and accepted this version of the article. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Our institution does not require ethical approval for reporting individual cases or case series.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: We thank Pasquale Del Vecchio for the bibliometric analysis.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Weidner, W.; Schroeder-Printzen, I.; Weiske, W.H.; Vossenrichter, R. Sexual dysfunction in Peyronie’s disease: An analysis of 222 patients without previous local plaque therapy. J. Urol. 1997, 157, 325–328. [CrossRef] 
2. Pryor, J.P.; Ralph, D.J. Clinical presentations of Peyronie’s disease. Int. J. Impot. Res. 2002, 14, 414–417. [CrossRef] [PubMed] 
3. Nelson, C.J.; Diblasio, C.; Kendirci, M.; Hellstrom, W.; Gehringer, P.; Mulhall, J.P. The chronology of depression and distress in men with Peyronie’s disease. J. Sex. Med. 2008, 5, 1985–1990. [CrossRef] [PubMed] 
4. Schwarz, U.; Sommer, F.; Klotz, T.; Braun, M.; Reifenrath, B.; Engelmann, U. The prevalence of Peyronie’s disease: Results of a large survey. BJU Int. 2001, 88, 727–730. [CrossRef] [PubMed] 
5. DiBenedetti, D.B.; Nguyen, D.; Zografos, L.; Ziemiecki, R.; Zhou, X. A Population-based study of peyronies disease: Prevalence and treatment patterns in the United States. Adv. Urol. 2011, 2011, 282503. [CrossRef] [PubMed] 
6. Segundo, A.; Cina, S. Prevalence, Risk Factors, and Erectile Dysfunction Associated with Peyronie’s Disease Among Men Seeking Urological Care. Sex. Med. 2020, 8, 230–236. [CrossRef] 
7. Devine, C.J., Jr.; Somers, K.D.; Ladaga, L.E. Peyronie’s disease: Pathophysiology. Prog. Clin. Biol. Res. 1991, 370, 355–358. 
8. Jarow, J.P.; Lowe, F.C. Penile trauma: An etiologic factor in Peyronie’s disease and erectile dysfunction. J. Urol. 1997, 158, 1388–1390. [CrossRef] 
9. Devine, C.J., Jr.; Somers, K.D.; Jordan, G.H.; Schlossberg, S.M. Proposal: Trauma as a cause of Peyronie’s lesion. J. Urol. 1997, 157, 285–290. [CrossRef] 
10. Somers, K.D.; Dawson, D.M. Fibrin deposition in Peyronie’s disease plaque. J. Urol. 1997, 157, 311–315. [CrossRef] 
11. Sikka, S.C.; Hellstrom, W.J. Role of oxidative stress and antioxidants in Peyronie’s disease. Int. J. Impot. Res. 2002, 14, 353–360. [CrossRef] [PubMed] 
12. Paulis, G.; Romano, G.; Paulis, L.; Barletta, D. Recent Pathophysiological Aspects of Peyronie’s Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review. Adv. Urol. 2017, 2017, 4653512. [CrossRef] [PubMed] 
13. El-Sakka, A.I.; Salabas, E.; Dinçer, M.; Kadioglu, A. The pathophysiology of Peyronie’s disease. Arab. J. Urol. 2013, 11, 272–277. [CrossRef] [PubMed] 
14. Levine, L.A.; Larsen, S. Diagnosis and Management of Peyronie Disease. In Campbell-Walsh Urology, 11th ed.; Wein, A.J., Kavoussi, L.R., Partin, A.W., Peters, C.A., Eds.; Elsevier Saunders: Philadelphia, PA, USA, 2015; pp. 722–748. 
15. Chung, E.; Ralph, D.; Kagioglu, A.; Garaffa, G.; Shamsodini, A.; Bivalacqua, T.; Broderick, G. Evidence-based management guidelines on Peyronie’s disease. J. Sex. Med. 2016, 13, 905–923. [CrossRef] [PubMed] 
16. Nguyen, H.N.T.; Anaisse, J.; DeLay, K.J.; Yafi, F.A.; Sikka, S.C.; Hellstrom, W.J. Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie’s disease. J. Sex. Med. 2017, 14, 1220–1225. [CrossRef] [PubMed] 
17. Eri, L.M.; Thomassen, H.; Brennhovd, B.; Håheim, L.L. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis. 2002, 5, 273–278. [CrossRef] 
18. Lee, J.S.; Chung, B.H. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens. Urol. Int. 2007, 78, 323–327. [CrossRef] 
19. Paulis, G.; Cavallini, G.; De Giorgio, G.; Quattrocorci, S.; Brancato, T.; Alvaro, R. Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie’s disease (chronic inflammation of the tunica albuginea). Results of a controlled study. Inflamm. Allergy Drug Targets 2013, 12, 403–409. [CrossRef] 
20. Favilla, V.; Russo, G.I.; Privitera, S.; Castelli, T.; Madonia, M.; La Vignera, S.; Morgia, G. Combination of intravesical verapamil and oral antioxidants for Peyronie’s disease: A prospective, randomised controlled study. Andrologia 2014, 46, 936–942. [CrossRef] 
21. Paulis, G.; Barletta, D.; Turchi, P.; VIarelli, A.; Dachille, G.; Fabiani, A.; Gennaro, R. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie’s disease: A case-control study. Res. Rep. Urol. 2016, 8, 1. [CrossRef] 
22. Gallo, L.; Sarnacchiaro, P. Ten-year experience with multimodal treatment for acute phase Peyronie’s disease: A real life clinical report. Actas Urol. Esp. 2019, 43, 182–189. [CrossRef] [PubMed] 
23. Paulis, G.; De Giorgio, G. Complete Plaque Regression in Patients with Peyronie’s Disease after Multimodal Treatment with Antioxidants. A Report of 2 Cases. Am. J. Case Rep. 2022, 23, e936146. [CrossRef] [PubMed] 
24. Kwon, K.D.; Choi, M.J.; Park, J.M.; Song, K.M.; Kwon, M.; Batbold, D.; Suh, J.K. Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie’s disease. BJU Int. 2014, 114, 926–936. [CrossRef] [PubMed] 
25. Ji, Q.; Zhang, L.; Jia, H.; Xu, J. Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines. Ann. Clin. Lab. Sci. 2004, 34, 427–436.
26. Karlsen, A.; Paur, I.; Bøhn, S.K.; Sakhi, A.K.; Borge, G.I.; Serafini, M.; Blomhoff, R. Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. *Eur. J. Nutr.* **2010**, *49*, 345–355. [CrossRef]

27. Bufalo, M.C.; Ferreira, I.; Costa, G.; Francisco, V.; Liberal, J.; Cruz, M.T.; Sforcin, J.M. Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF-κB and MAPK activation in macrophages. *J. Ethnopharmacol.* **2013**, *149*, 84–92. [CrossRef]

28. Wang, Y.; Wang, R.; Wang, Y.; Peng, R.; Wu, Y.; Yuan, Y. Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling. *Drug Des. Dev. Ther.* **2015**, *9*, 6303–6317.

29. Tian, M.Y.; Fan, J.H.; Zhuang, Z.W.; Dai, F.; Wang, C.Y.; Hou, H.T.; Ma, Y.Z. Effects of silymarin on p65 NF-κB, p38 MAPK and CYP450 in LPS-induced hoof dermal inflammatory cells of dairy cows. *BMC Vet. Res.* **2019**, *15*, 127. [CrossRef]

30. McCauley, J.F.; Dean, R.C. Diagnostic utility of penile ultrasound in Peyronie’s disease. *World J. Urol.* **2020**, *38*, 263–268. [CrossRef]

31. Hatzimouratidis, K.; Eardley, I.; Giuliano, F.; Hatzichristou, D.; Moncada, I.; Salonia, A.; Wespies, E. EAU guidelines on penile curvature. *Eur. Urol.* **2012**, *62*, 543–552. [CrossRef]

32. Parmar, M.; Masterson, J.M.; Masterson, T.A., 3rd. The role of imaging in the diagnosis and management of Peyronie’s disease. *Curr. Opin. Urol.* **2020**, *30*, 283–289. [CrossRef] [PubMed]